Lessons from COVID-19 to increase opioid vaccine acceptance

COVID-19 has put vaccine efficacy under a spotlight. However, the reluctance of people to be vaccinated has postponed the end of the COVID-19 pandemic. Currently, opioid vaccines are being developed, which could help prevent opioid addiction, overdoses, or relapse in combination with medication-assi...

Descripción completa

Detalles Bibliográficos
Autores principales: Damiescu, Roxana, Banerjee, Mita, Paul, Norbert W., Efferth, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Science & Society
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448697/
https://www.ncbi.nlm.nih.gov/pubmed/36123169
http://dx.doi.org/10.1016/j.tips.2022.08.010
Descripción
Sumario:COVID-19 has put vaccine efficacy under a spotlight. However, the reluctance of people to be vaccinated has postponed the end of the COVID-19 pandemic. Currently, opioid vaccines are being developed, which could help prevent opioid addiction, overdoses, or relapse in combination with medication-assisted therapy. The fear is that the uptake of opioid vaccines could be met by the same reluctance as seen with COVID-19 vaccines.

Ejemplares similares